Cabaletta Bio stockholders approve doubling authorized common shares to 300M, elect directors at annual meeting

Cabaletta Bio, Inc.

Authorized shares increased from 150M to 300M; approved by 32.6M for vs 2.0M against.
Steven Nichtberger, M.D. and Mark Simon, MBA re-elected as Class III directors through 2028.
Ernst & Young LLP ratified as independent auditor for fiscal year ending Dec 31, 2025.
Say-on-pay approved with 52% support; stockholders selected annual frequency for future advisory votes.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Cabaletta Bio, Inc.: Increased number of authorized shares of common stock from 150,000,000 to 300,000,000 (effective 2025-06-09).

Change: charter amendment
Effective: 2025-06-09

Exact text from the filing

On June 9, 2025, the Company filed a Certificate of Amendment to the Company’s Third Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware and the Certificate of Amendment became effective on filing.

View on SEC.gov

Browse all governance changes →

Cabaletta Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-137954

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.